Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BIOA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| BGE-117 | Anemia | Phase 2 · NCT04815603 | Withdrawn |
| BGE-175 | Covid19 | Phase 2 · NCT04705597 | Terminated |
| Azelaprag | Obesity | Phase 2 · NCT06515418 | Terminated |
| Oral BGE-102 | Obesity and Cardiovascular Risk | Phase 2 · NCT07656727 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not BIOA's own candidates): Bevacizumab, Tirzepatide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BIOA holds $352.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.1M/quarter from operations, an estimated runway of 42.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 24 · Moderate
Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the filing date of this Quarterly Report will be sufficient to fund our operations and capital expenses through 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIOA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vijay Satyanand Pande Director · +44,000 options |
Insider | 3,233,170 | 7.03% | 2024-10-01 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,236,460 | 4.87% | 2026-03-31 |
| Kristen Fortney Chief Executive Officer, Director · +860,000 options |
Insider | 976,949 | 2.13% | 2026-01-13 |
| Dov A Md Goldstein Chief Financial Officer · +358,420 options |
Insider | 36,575 | 0.08% | 2026-04-23 |
| Rekha Hemrajani Director · +44,000 options |
Insider | 3,000 | 0.01% | 2024-04-17 |
Share count 45,958,509 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIOA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →